Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
in terms of revenue improvements and major cost reductions: http://www.investegate.co.uk/akers-biosciences--akr-/rns/3rd-quarter-results/201611140700080297P/ $800,000 cash in hand, with $2m due from Novatek in the next month (before 31st December), so hopefully this will run smoothly. The concluding outlook reads extremely well - notably re profitability next year: "Outlook Akers Bio moves into the final quarter of 2016 with excellent momentum in domestic sales of our flagship rapid test for HIT and with the remaining $2,000,000 due under the Novotek order for products in China which we expect to be fulfilled in the fourth quarter. There is also evidence of further demand for Akers Wellness™ products which are expected to produce additional sales in the remaining months of the year. The combination of these growing product sales and a leaner cost base is expected to enable Akers Bio to trade profitably both in the final quarter and, more significantly, in 2017."
Http://www.investegate.co.uk/akers-biosciences--akr-/rns/european-patent-granted/201611100700098033O/ The breath test for diabetics seems like a potentially huge winner imho, backed up by the comment in the RNS: "The technology has a large number of potential mass-market applications, including within health and wellness, but in particular, we believe the ability to help Type 1 and some Type 2 diabetics monitor their ketone levels in a non-invasive, convenient format will be a significant advancement in the management of a disease that affects hundreds of millions of people worldwide," added Dr. Akers."
Chartest
Stockinvest.US/comment.aker Put into search bar akers or akers bioscience and you get a every day charters estimation of what is expected from akers bioscience for the next 3 months
Great to see two pieces of good news in the last week: The Chubeworks settlement is particularly good news since the entire $1.25m had already been written off, whereas now AKR will receive a very useful $500k of cash plus $750k of stock for resale: http://www.investegate.co.uk/akers-biosciences--akr-/rns/settlement-of-dispute-with-chubeworkx/201608190700066059H/ And also the successful results of the Oxichek test study: http://www.investegate.co.uk/akers-biosciences--akr-/rns/results-of-oxichek-test-study/201608180700084834H/
Http://www.proactiveinvestors.com/companies/news/127675/akers-delighted-with-chlamydia-trial-results-127675.html "Akers 'delighted' with chlamydia trial results 10:22 30 Jun 2016 The assessment of the company's PIFA assay took place at two centres in the Pennsylvania in the US. Shares in Akers Biosciences Inc (NASDAQ:AKER, LON:AKR) were up almost a quarter in London following the release of results from a trial of its rapid diagnostic for chlamydia, which the company itself described as “highly successful”. The assessment of the company's PIFA assay took place at two centres in the Pennsylvania in the US. The system, which uses a finger stick blood sample, matched the findings of lab tests in 96% of the cases. Lab testing is the gold standard method of screening for chlamydia, but it can take up to 10 days to deliver the results. This is time consuming, costly and stressful for the patient. The PIFA system gives a read-out in just five minutes. The company’s founder Raymond Akers said: “It is a very exciting outcome to have a five-minute rapid test demonstrate that level of accuracy. “This bodes well not only for the PIFA/Chlamydia Rapid Assay but for our other proprietary PIFA technology based tests in development." The shares rose 40p to 210p. The trial results were the second piece of good news of the week. On Monday Akers said it signed up its first distribution agreement for BreathScan OxiChek, a device that monitors oxidative stress in the body. The deal is with Aero-Med, a division of American Fortune 500 healthcare services group Cardinal Health, and a roll-out will start with a team focussing on the New England region of the United States. Aero-Med is expected to target large US markets; for example anti-aging, functional and integrative health and wellness treatment. "
Up to $3.32 in the USA (changing all the time), and on huge volumes too - that's around 240p in UK terms.
Akers is now becoming a real positive investment story . New CEO with a proven track record and demonstrating his sales expertise right now R.akers now back in the LAb were he excels This small company could possible be huge globally with its unique proprietary technology I'm genuinely excited about its future now
The UK share price is still behind last night's close in the USA of $2.78. After today's news is announced in the USA this afternoon things could get extremely interesting over there.
Wow - AKR today announce the "highly successful" completion of a trial for "the first rapid test for Chlamydia diagnosis using a finger stick blood sample": Http://www.investegate.co.uk/akers-biosciences--akr-/rns/clinical-trial-for-rapid-chlamydia-test-completed/201606300700097101C/ Imagine the potential for this test and the potential global take-up.... There's certainly nothing in the share price for this on a mere £9m m/cap.
Up to $2.85 in the USA this afternoon - that's around 210p at current rates. Brexit is at least good for foreign-denominated stocks! Terrific volumes too in the USA with 1,400,000 shares traded already.
Nice - a first distribution agreement for OxiChek is with the mighty Cardinal Health (via Aero-Med). And some orders already placed: Http://www.investegate.co.uk/akers-biosciences--akr-/rns/distribution-agreement-for-breathscan-oxichekt/201606270700072724C/ "Dan DelMastro, CEO of Aero-Med added, "Aero-Med recognizes the enormous market potential for products within the health and wellness sector so we are delighted to be incorporating OxiChek into our sales offering. Having personally observed the positive customer reaction to OxiChek at conventions in recent months, I am optimistic that there is strong potential for this product."
"Akers’ HIT diagnostic key to short term growth, says finnCap 16:19 17 Jun 2016 House broker finnCap has reintroduced estimates for Akers Biosciences Inc (LON:AKR) and is predicting a steep uplift in sales. The broker unveiled a forecast of US$5.6mln in revenues for 2016, up from US$2.1mln in 2015, with 88% growth in the flagship PIFA Heparin/PF4 rapid assay products. Mark Brewer, analyst at broker finnCap says, the medical diagnostic maker, has the potential for stronger growth in the second half of the year “through the launch of new products”. “The core and the key to driving growth in the short term is how well they do with the heparin-induced thrombocytopenia diagnostic” he adds. Brewer’s note inspired a 10% rise in Aker’s shares. The stock has gained 73% since the start of 2016. http://www.proactiveinvestors.co.uk/companies/stocktube/5160/akers-hit-diagnostic-key-to-short-term-growth-says-finncap-5160.html
http://tinyurl.com/hfvbe4y Raymond Akers, executive chairman of Akers Biosciences Inc (NASDAQ:AKER, LON:AKR) says the company has “paved the way for significant sales of our flagship product both in the US and China” and has “already started to see the results”. The firm announced today that orders for its rapid heparin allergy test total more than US$3mln, with $2.5mln from China, as well as a 70% rise in demand from the US in the first quarter. Akers says, with the expanded order book, that he expects to be cash generative in the second half of this year.
http://tinyurl.com/zot8zjp Raymond Akers, founder and executive chairman of Akers Biosciences Inc (NASDAQ:AKER, LON:AKR), says “this is gonna be a great year” after a “blazing start” to 2016. The diagnostic test maker has been granted a US patent for the technology at the heart of a test that detects an allergy to the blood thinning drug Heparin. The patent was just the tip of the iceberg as the group expands its reach. “We now have distribution in 33 countries around the world," says Akers who added the US$2.5mln order it received from China was a “taste of things to come.”
Nice: http://www.investegate.co.uk/akers-biosciences--akr-/rns/-2-5m-product-order/201603020700087103Q/
Published on Nov 13, 2015 https://www.youtube.com/watch?v=3fcsTRSRFkg Ray Akers, chief executive of Akers Biosciences (LON:AKR) says ordering patterns from distributors are returning to normal levels after a weaker third quarter. Akers’ Heparin devises - used by more than 200 US hospitals - remain the only US FDA-cleared rapid manual assays that determine if a patient being treated with the blood thinner may be developing HIT. Patients suffering HIT are at risk of developing limb-and life-threatening complications, so the timely test result is paramount to effective, clinical decision making. The CEO reckons at the current growth rate, the HIT test could be used in close to 500 hospitals by December, 2016.
Great RNS - the Chinese FDA have approved "for medical use throughout Mainland China the Company's flagship rapid tests for allergic reactions associated with the widely used blood-thinner, heparin." With Novotek already in place as the distributor, this is excellent news for a mere £9m m/cap company. And Akers' test is the first and only such test of its kind in China. Consider the size of Novotek: "NovoTek Therapeutics Inc. is a vital part of NovoTek Group, and is in charge of all international business. To date, NovoTek Group has grown to seven subsidiary companies focused on pharmaceutical marketing, medical and IVD products marketing, and contract research services. NovoTek has its own preclinical research facility, clinical trial and regulatory teams, and more than 600 sales representatives (500 for pharmaceuticals and 100 for medical devices) across China. NovoTek has more than 800 employees and more than 10 local branches nationwide. www.novotekchina.com "
....of the new wellness tests: Http://www.investegate.co.uk/akers-biosciences--akr-/rns/commercialization-of-new-breath-tests/201510060700123038B/ "Akers Biosciences, Inc. Commercializes New App-Enabled Tests for Health and Wellness Industry and Consumers Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a medical device company focused on reducing the cost of healthcare through faster, easier diagnostics, announces that all development specifications have been finalized and production has commenced for its two transformational breath tests designed for the health and wellness industry and consumers. Akers Bio is launching the BreathScan OxiChek™ ("OxiChek") and BreathScan KetoChek™ ("KetoChek") tests this week at the Supply Side West conference in Las Vegas, Nevada. The conference focuses on dietary supplements and sports nutrition, two key markets for these new products. OxiChek is the first disposable breath test to rapidly determine levels of oxidative stress (free radicals) in the body. OxiChek measures the most abundant free radicals including superoxides, hydrogen peroxide and aldehydes - unlike some pre-existing devices which measure only one. Frequent use of OxiChek may help consumers and professional clients manage and adhere to their regimen of nutritional supplementation for management of oxidative stress, which is implicated in many diseases, including cardiac, cancer and arthritic diseases. KetoChek, and the Company's non-quantitative version, METRON®, are the only disposable breath-based diagnostic devices that rapidly determine if the subject is in the optimal fat-burning state for weight loss, known as ketosis. Achieving a state of ketosis - as indicated by the measure of breath ketones - is a goal of many individuals following low carbohydrate diets. KetoChek is a simple, non-invasive test to identify, track and quantitatively monitor breath ketones for individuals interested in maximizing weight loss... .."The response to the Akers Wellness products has been overwhelmingly positive," said Raymond F. Akers, Jr. PhD, Co-founder and Executive Chairman. "We launched our first product, METRON®, into this market last month, including through the Amazon marketplace. Now, the Company is expanding its market reach through our efforts at Supply Side West, targeting multi-level marketing companies in the nutraceutical business, fitness and weight loss centers, chiropractors, and anti-aging medicine physicians. The Company is aggressively seeking distribution into these market segments," continued Dr. Akers. "We believe that consumers are increasingly looking for personalized health, and that the BreathScan platform will provide the footprint for the Company to enter into the new era of digital medicine. Our new health and wellness products are poised to make an impact now as we commence
Https://www.youtube.com/watch?v=n3IYf9oxO-s "Published on 1 Oct 2015 Raymond Akers, chief executive of Akers Biosciences (LON:AKR), reckons the global heparin-induced thrombocytopenia (HIT) test industry is not far away from being valued as a US$1bn market. Akers is a front runner in the space and has distribution for its own HIT test in every major diagnostic market after inking agreements for India, Germany, Italy and Scandinavia. Millions of patients are exposed to heparin around the world each year and between 1% and 5% of those patients receive a HIT diagnosis. The test is the only US and EU cleared rapid test to detect a potentially fatal allergy to the widely used blood thinner, heparin. That allergy reverses the effect of heparin and turns it into a clotting agent, which is clearly very dangerous."
Consolidation
hi. I use to own shares in aker in 2010. they was going nowhere and I sold out around 10p. can anyone tell me why the share price shot up from around 4p to £5 end of 2010. thanks
News....in particular: "The Company is in discussions with a number of strategic partners specializing in the health and wellness industry with regards to the commercialization of OxiChek™, KetoChek™, and BreathScan Lync™ Http://www.investegate.co.uk/akers-biosciences--akr-/rns/akers-introduces-new-rapid-breath-tests/201505120720398731M/ "Akers Biosciences Introduces New Rapid Breath Ketone and Oxidative Stress Tests to the Health and Wellness Industry Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a medical device company focused on reducing the cost of healthcare through faster, easier diagnostics, introduced two new breath tests to the U.S. market from the Company's Akers Wellness division at the World Congress on Anti-Aging Medicine in Hollywood, Florida, USA last week. etc"
Brief notes from last night's presentation - apologies if anything written down/understood incorrectly: Sales should be up to $7.2m this year, with breakeven during the period, and ending with approx.$10m cash (i.e almost 50% of the m/cap). AKR can produce $50m of sales from their existing facilities, so there's no need for material capital expenditure. Heparin test - the price of AKR's Heparin test is to be INCREASED from May 1st, due to the huge savings for hospitals - 10 new sales reps are each opening 3 new hospital/customer accounts per month, each selling $30k per annum, which I calculate to be $10.8m revenues per annum once a year's selling is up and running - there should be one or two further Chinese orders this year Cholesterol test is perfect for Australia given distances/flying doctors etcf, and has achieved $900,000 of unbudgeted sales 5 products currently on the market, growing soon to 11 Future products include (1) breath test for lung cancer, (2) test for type 1 diabetics, at 73% margins (this is AKR's lowest margin test!), (3) chlamydia test, to be perfected this summer after clinical trials. AKR's great advantage is that clinical trials only take a few months and cost relatively little. The diabetes test will be launched in China and USA this year. AKR already have a Chinese facility. I think he said the asthma test is this year too. There's no competition for the heparin and other breath tests (except the alcohol test in Europe).
Good to see 5,000 shares bought first thing this morning at 320p. Hopefully a reaction to last night's very good presentation by Ray Akers at Finncap (organised by Sharesoc), which reinforced my positive opinion about the company. More later.